[Special Stock] DRTech, Subsidiary Develops Independent Cancer Diagnosis... "99% Accuracy with Urine Test"

DRTech is showing strong performance. It appears that the news of its subsidiary SysBiogen independently developing early cancer diagnosis technology has had an impact.

As of 10:43 AM on the 15th, DRTech was trading at 4,090 KRW, up 425 KRW (11.60%) compared to the previous trading day.

SysBiogen is a bio company jointly led by An Seong-hyun, CEO of DRTech, and Choi Kwan-yong, honorary professor at Pohang University of Science and Technology. DRTech is the largest shareholder of SysBiogen, holding approximately 50% of shares including those of related parties.

In an interview with an economic newspaper on the same day, Choi Kwan-yong, CEO of SysBiogen and a subsidiary of DRTech, stated, "SysBiogen's prostate cancer diagnosis technology using urine showed an accuracy of 99% based on a study conducted on 163 patients at Asan Medical Center."

He also emphasized, "In the case of prostate cancer, early diagnosis can prevent 99% of cases," adding, "Worldwide, about 1.4 million new prostate cancer cases are diagnosed annually, making it the second most common malignant tumor among cancers affecting men."

SysBiogen is also developing early diagnosis technology for breast cancer. This technology analyzes genes through a liquid biopsy method using blood to assess the risk of breast cancer. The company explained that by collaborating with DRTech, which developed a breast cancer X-ray examination system, combining genetic and X-ray tests can increase diagnostic accuracy up to 88%.

This content was produced with the assistance of AI translation services.